These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34258237)

  • 1. Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT.
    Anda L; Johnsen E; Kroken RA; Joa I; Rettenbacher M; Løberg EM
    Schizophr Res Cogn; 2021 Dec; 26():100204. PubMed ID: 34258237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
    Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
    Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
    Mørkved N; Johnsen E; Kroken RA; Winje D; Larsen TK; Thimm JC; Rettenbacher MA; Johannesen CAB; Løberg EM
    Schizophr Res; 2022 Aug; 246():49-59. PubMed ID: 35709647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.
    Drosos P; Johnsen E; Bartz-Johannessen CA; Larsen TK; Reitan SK; Rettenbacher M; Kroken RA
    World J Psychiatry; 2022 Mar; 12(3):521-532. PubMed ID: 35433321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
    Sinkeviciute I; Hugdahl K; Bartz-Johannessen C; Kroken RA; Løberg EM; Kjelby E; Rettenbacher MA; Joa I; Reitan SK; Alisauskiene R; Fathian F; Johnsen E
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):389-396. PubMed ID: 33938520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine.
    Drosos P; Johnsen E; Bartz-Johannessen CA; Larsen TK; Reitan SK; Rettenbacher M; Kroken RA
    Schizophr Res; 2024 Jul; 271():9-18. PubMed ID: 39002529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole for schizophrenia.
    El-Sayeh HG; Morganti C
    Cochrane Database Syst Rev; 2006 Apr; (2):CD004578. PubMed ID: 16625607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the prescribing patterns of antipsychotic medication in a rural England Community Mental Health Team.
    Seshadri M; Elsemary A; Thalitaya MD; Chikodzore L; Nagalingam P
    Psychiatr Danub; 2017 Sep; 29(Suppl 3):524-529. PubMed ID: 28953820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole versus placebo for schizophrenia.
    Belgamwar RB; El-Sayeh HG
    Cochrane Database Syst Rev; 2011 Aug; (8):CD006622. PubMed ID: 21833956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
    Cuesta MJ; Peralta V; Zarzuela A
    Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.